I-Linagliptin

Igama Lekhemikhali:

8-[(3R)-3-aminopiperidin-1-yl]-7-(kodwa-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3 ,7-dihydro-1H-purine-2,6-dione

Ikhodi ye-SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Ikhodi ye-InChi:

I-InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33(23(21 )34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2 ,1-3H3/t17-/m1/s1

I-InChi Key:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Igama elingukhiye:

I-Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Ukunyibilika:I-Soluble ku-DMSO

Isitoreji:0 - 4°C isikhathi esifushane (izinsuku ukuya emavikini), noma -20°C isikhathi eside (izinyanga).

Incazelo:

I-Linagliptin, eyaziwa nangokuthi i-BI-1356, iyi-DPP-4 inhibitor eyakhiwe ngu-Boehringer Ingelheim ekwelapheni uhlobo lwesifo sikashukela sohlobo II. I-Linagliptin (kanye ngosuku) yagunyazwa yi-US FDA ngomhlaka-2 Meyi 2011 ukuze kwelashwe uhlobo lwesifo sikashukela sohlobo II. Imakethwa nguBoehringer Ingelheim noLilly.

Ithagethi: DPP-4